Trillium Asset Management LLC Has $4.56 Million Position in TransMedics Group, Inc. $TMDX

Trillium Asset Management LLC cut its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 3.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,034 shares of the company’s stock after selling 1,355 shares during the quarter. Trillium Asset Management LLC owned 0.10% of TransMedics Group worth $4,561,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. OneDigital Investment Advisors LLC increased its position in TransMedics Group by 52.6% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company’s stock worth $403,000 after purchasing an additional 2,065 shares in the last quarter. Principal Financial Group Inc. increased its position in TransMedics Group by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock worth $13,350,000 after purchasing an additional 5,480 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in TransMedics Group during the 1st quarter worth approximately $291,000. New York State Teachers Retirement System increased its position in TransMedics Group by 183.2% during the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock worth $1,477,000 after purchasing an additional 14,200 shares in the last quarter. Finally, Valmark Advisers Inc. increased its position in TransMedics Group by 34.6% during the 2nd quarter. Valmark Advisers Inc. now owns 9,709 shares of the company’s stock worth $1,301,000 after purchasing an additional 2,496 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TMDX has been the subject of a number of research analyst reports. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Morgan Stanley boosted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Piper Sandler reduced their target price on shares of TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Finally, Jefferies Financial Group assumed coverage on shares of TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.73.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the transaction, the director owned 2,866 shares in the company, valued at $373,869.70. The trade was a 59.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Trading Up 1.8%

NASDAQ:TMDX opened at $124.46 on Thursday. The firm’s fifty day moving average is $117.52 and its 200-day moving average is $118.40. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $145.50. The firm has a market cap of $4.25 billion, a P/E ratio of 50.39 and a beta of 2.05.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. During the same period in the prior year, the firm posted $0.12 EPS. The company’s quarterly revenue was up 32.2% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. Equities analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.